Browse the evidence

Semaglutide treatment is associated with a significantly higher risk of diabetic retinopathy complications compared to placebo in patients with type 2 diabetes, particularly those with preexisting retinopathy.

If you have type 2 diabetes and are taking semaglutide, be aware that it may increase the risk of eye problems, especially if you already have diabetic retinopathy. Regular eye exams are essential to monitor for any changes. The cardiovascular benefits of semaglutide are significant, but managing eye health is a critical part of your overall care plan.

Beta-3 adrenergic receptors are not strictly required for brown adipose tissue function or thermogenesis, as evidenced by species lacking them (guinea pigs) or mice genetically ablated for beta-3 receptors, which compensate via beta-1 receptors.

You do not need beta-3 receptors to activate brown fat. The body can use beta-1 receptors to achieve the same thermogenic result if beta-3 receptors are absent or non-functional.

Conjugated equine estrogen (CEE) alone does not reduce the incidence of coronary heart disease in postmenopausal women with prior hysterectomy.

If you have had a hysterectomy and are considering hormone therapy for heart disease prevention, current evidence shows it does not work for that purpose. While it may help with bone density (hip fractures), it increases stroke risk. Do not use CEE solely to protect your heart.

Conjugated equine estrogen (CEE) increases the risk of stroke in postmenopausal women with prior hysterectomy.

If you are considering CEE for menopausal symptoms, be aware that it increases your risk of stroke by about 39%. This risk is significant enough that CEE is not recommended for chronic disease prevention.

Conjugated equine estrogen (CEE) reduces the risk of hip fractures in postmenopausal women with prior hysterectomy.

CEE reduces hip fracture risk, which is a benefit for bone health. However, because it increases stroke risk and does not prevent heart disease, it is not recommended solely for disease prevention.

Lifelong genetic reduction of LDL cholesterol via PCSK9 sequence variations significantly reduces the incidence of coronary heart disease, with protection persisting despite high prevalence of non-lipid-related cardiovascular risk factors.

Your genetic makeup can influence your cholesterol, but the most powerful thing you can do for your heart health is to keep your LDL levels low throughout your entire life, not just when you get older. This study shows that maintaining low LDL from a young age offers superior protection against heart disease, even if you have other risk factors like high blood pressure or diabetes. Focus on lifelong management of lipid levels rather than waiting for symptoms or later years to intervene.

Increased expression of Monocyte Chemoattractant Protein-1 (MCP-1) in adipose tissue directly causes macrophage infiltration, insulin resistance, and hepatic steatosis in obesity.

This research identifies MCP-1 as a key link between fat tissue and insulin resistance. While this is a mouse study, it suggests that therapies targeting MCP-1 or its receptor (CCR2) could potentially treat insulin resistance and fatty liver in obese humans by reducing fat tissue inflammation.

The metabolic syndrome is an imprecise and clinically unhelpful diagnostic construct for predicting cardiovascular disease risk because its definition is ambiguous, its underlying pathophysiology is uncertain, and it offers no predictive advantage over treating individual risk factors.

Do not wait for a 'metabolic syndrome' diagnosis to manage your heart health. If you have high blood pressure, high blood sugar, or abnormal cholesterol, treat those specific issues directly. The concept of 'metabolic syndrome' is too vague and does not add value to standard risk assessment. Focus on controlling your individual risk factors through lifestyle and medication as prescribed, rather than worrying about meeting a specific syndrome threshold.

Combined estrogen plus progestin hormone therapy does not prevent coronary heart disease and increases the risk of CHD, particularly during the first year of use.

Do not use estrogen plus progestin to prevent heart disease. For postmenopausal women with an intact uterus, this combination increases the risk of coronary heart disease, especially in the first year of use. It should not be prescribed for cardiovascular prevention.

Endogenous GLP-1 is primarily secreted by intestinal L-cells in response to nutrient contact, not by pancreatic alpha-cells.

Your body naturally produces GLP-1 from your intestines when you eat. This hormone helps regulate blood sugar and appetite. Dietary fiber and nutrients stimulate this natural release.

Native GLP-1 has a very short half-life (1-2 minutes) due to rapid degradation by the enzyme DPP-4, necessitating biochemically modified agonists for clinical use.

Your body breaks down natural GLP-1 very quickly. Medications like Ozempic or Wegovy are chemically modified to resist this breakdown, allowing them to work for days instead of minutes.

Obesity-induced insulin resistance is mechanistically driven by the activation of serine/threonine kinases (such as JNK, IKK, and PKC isoforms) which phosphorylate insulin receptor substrates (IRS) on inhibitory serine residues, thereby blocking normal tyrosine phosphorylation and signal transduction.

Insulin resistance in obesity is not just 'bad luck'; it is a specific biological response to stressors like excess lipids and inflammation. These stressors trigger specific enzymes (kinases) that physically block insulin's ability to signal. Understanding this means recognizing that reducing these stressors (via weight loss, exercise, or metabolic health improvements) can reverse the signaling block.

Genetic mutations in the insulin receptor gene cause rare, severe forms of insulin resistance (e.g., leprechaunism), but these mutations are not observed in routine type-2 diabetes.

Unlike rare genetic disorders, common type-2 diabetes is not caused by broken insulin receptor genes. It is a functional problem of how cells respond to insulin, driven by lifestyle and metabolic factors.

FFAR3 (GPR41) is dispensable for normal body weight, adiposity, and glucose homeostasis in mice, and is not required for the obesity-protective effects of butyrate and propionate.

The receptor FFAR3 (GPR41) is not required for maintaining normal body weight, fat levels, or blood sugar control in mice. This suggests that other mechanisms can compensate for its absence, and that therapies targeting FFAR3 might not be strictly necessary for basic metabolic health.

SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) reduce cardiovascular mortality, overall mortality, and heart failure hospitalizations in patients with type 2 diabetes and established cardiovascular disease, independent of glycemic control.

If you have type 2 diabetes and existing heart disease, SGLT2 inhibitors (like empagliflozin, dapagliflozin, or canagliflozin) are now recommended not just for blood sugar, but to significantly lower your risk of heart failure, heart attack, stroke, and death. This benefit exists even if your blood sugar control doesn't change much, suggesting the drug protects your heart and kidneys directly.

Activation of the NLRP3 inflammasome in macrophages leads to the secretion of IL-1β and IL-18, which impair insulin signaling and contribute to beta-cell apoptosis in Type 2 Diabetes.

Chronic inflammation in fat tissue activates specific immune pathways (NLRP3 inflammasome) that release harmful cytokines (IL-1β). These cytokines damage insulin signaling and beta-cells. Addressing inflammation may help protect these cells.

Perilipin acts as a dynamic scaffold on adipocyte lipid droplets that restricts basal lipolysis by blocking cytosolic lipase access, and upon PKA phosphorylation during energy deficit, facilitates maximal lipolysis by coordinating the docking of hormone-sensitive lipase and adipose triglyceride lipase.

Your body uses a protein called perilipin to manage fat storage. When you are not exercising or fasting (basal state), perilipin acts as a shield, preventing enzymes from breaking down stored fat. When you create an energy deficit (e.g., through exercise or fasting), hormones trigger a signal (PKA) that phosphorylates perilipin. This changes its shape, removing the shield and allowing fat-burning enzymes (ATGL and HSL) to access and break down the fat. Without this protein's dynamic regulation, your body cannot efficiently switch between storing and burning fat.

Insulin signaling promotes lipid synthesis and glucose storage by upregulating SREBP-1c and ChREBP, while simultaneously repressing gluconeogenic genes via the inhibition of FOXO transcription factors.

Insulin acts as a master switch for energy storage. When insulin is high (after eating), it turns on genes that store fat and glucose, and turns off genes that produce new glucose. This is why high-insulin states favor fat storage.

Albumin binding via fatty acid derivatization extends the half-life of GLP-1 analogs, enabling once-daily (liraglutide) or once-weekly (semaglutide) dosing.

The drugs are designed to bind to albumin in the blood, which keeps them in the body longer. This allows for less frequent dosing (daily or weekly) compared to the natural hormone, which breaks down quickly.

Type 2 deiodinase (D2) is retained in the endoplasmic reticulum (ER), allowing locally generated T3 to have prolonged access to nuclear thyroid hormone receptors compared to T3 entering from the plasma.

The location of thyroid hormone production matters. When D2 produces T3 inside the cell (in the ER), that T3 stays near the nucleus longer than T3 coming from the blood, ensuring stronger local signaling.

Loss-of-function mutations in PPARγ cause a syndrome of partial lipodystrophy and severe insulin resistance, demonstrating that PPARγ is essential for normal adipose tissue function and metabolic health.

This node describes a rare genetic condition, not a general lifestyle advice. It proves that healthy fat tissue is crucial for preventing diabetes.

Type 2 diabetes risk in Europeans is predominantly driven by common genetic variants of modest effect size, with no novel low-frequency variants of moderate-to-strong effect detected despite extensive sample sizes.

This research indicates that for most people of European ancestry, Type 2 Diabetes risk is largely determined by common genetic factors with small individual effects, rather than rare, high-impact mutations. This means lifestyle interventions remain critical because they address the environmental and physiological pathways (insulin secretion, action) that these genes influence, even if the genetic risk itself cannot be changed.

PPARγ is the master regulator of adipogenesis; its presence is necessary and sufficient for the differentiation of precursor cells into mature adipocytes, whereas its absence prevents fat cell formation.

Understanding that PPARγ is the master switch for fat cells helps explain why obesity is hard to reverse once established, but also why targeting this pathway (e.g., with specific drugs or lifestyle changes like fasting) can be effective. It is not just 'willpower'; it is a molecular process that can be modulated.

Glucotoxicity and lipotoxicity are major factors causing progressive beta-cell failure in type 2 diabetes through apoptosis.

High blood sugar (glucotoxicity) and high fatty acids (lipotoxicity) kill beta-cells in type 2 diabetes. Managing these levels is crucial to prevent further loss of insulin-producing capacity.